Anti-neuroinflammatory activity of Shenqi Fuzheng Injection and its main active constituents

Wang, Wenwen; Zhang, Zijia; Deng, Yanping; Yang, Zhengming; Hou, Jinjun; Long, Huali; Lei, Min; Wu, Wanying

doi:10.5582/bst.2021.01140

Cited by 1 publication

(1 citation statement)

References 41 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A Shenqi Fuzheng injection is a Chinese patent medicine approved by the CFDA in 1999. It consists of two traditional Chinese herbs, Radix Astragali (Huangqi) and Codonopsis Pilosula (Dangshen) at a ratio of 1:1 (Figure 6B), and it is commonly used to improve immune function in chronic diseases including cancer and cerebrovascular diseases such as, angina, coronary heart disease, and heart failure (2,66). Recently, a number of trials have indicated that a Shenqi Fuzheng injection might play an important role in the treatment of various advanced cancers such as NSCLC and gastric cancer.…”

Section: A Shenqi Fuzheng Injectionmentioning

confidence: 99%

Recent advances in Chinese patent medicines entering the international market

Zhang

Pei

Cai

et al. 2022

DD&T

View full text Add to dashboard Cite

Chinese patent medicines, global acceptance, respiratory infectious diseases, cardiovascular and cerebrovascular diseases, cancers, gynecological diseases As an indispensable part of Traditional Chinese medicine (TCM), Chinese patent medicines have played an important role in preventing and treating diseases in China. Since they are easy to use, easy to store, and cost-effective, Chinese patent medicines have been generally accepted and widely used in Chinese clinical practice as a vital medical resource. In recent years, as TCM has developed and it has been accepted around the world, many Chinese patent medicine companies have gained international market access and successfully registered several Chinese patent medicines as over-thecounter (OTC) or prescription drugs in regions and countries that primarily use Western medicine such as the EU, Russia, Canada, Singapore, and Vietnam. Moreover, several Chinese patent medicines have been obtained the US Food and Drug Administration (FDA) approval conducting phase II or III clinical trials in the US. The current work has focused on several Chinese patent medicines that have been successfully registered or that have been submitted for registration abroad. Summarized here are recent advances in the efficacy and molecular mechanisms of these Chinese patent medicines to treat respiratory infectious diseases (Lianhua Qingwen capsules, Jinhua Qinggan granules, and Shufeng Jiedu Capsules), cardiovascular and cerebrovascular diseases (Compound Danshen Dripping Pills, Huatuo Zaizao pills, and Tongxinluo Capsules), cancers (a Kanglaite injection and a Shenqi Fuzheng Injection), and gynecological diseases (Guizhi Fuling Capsules). The hope is that this review will contribute to a better understanding of Chinese patent medicines by people around the world.

show abstract

Section: A Shenqi Fuzheng Injectionmentioning

confidence: 99%